Drugs / Gold Nanocrystals
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03843710 | Mar 2020 → Feb 2022 | amyotrophic lateral sclerosis | Clene Nanomedicine | Withdrawn | No outcome recorded |
| Phase 2 | NCT03993171 | Dec 2019 → May 2025 | multiple sclerosis | Clene Nanomedicine | Completed | No outcome recorded |
| Phase 2 | NCT03815916 | Dec 2019 → Jun 2021 | Parkinson disease | Clene Nanomedicine | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gold Nanocrystals | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03843710 ↗ |
| Known as | CNM-Au8 | “CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with...” NCT03815916 ↗1“CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water” NCT03843710 ↗ |
| Modality | Other / unclassified | “stable suspension of faceted clean surfaced elemental gold nanocrystals” NCT03843710 ↗ |
| Route | Oral | “The drug product is formulated to be taken orally” NCT03815916 ↗ |